Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period.

Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Giacomet V, Bernardi S, Esposito S, Rosso R, Giaquinto C, Badolato R, Guarino A, Maccabruni A, Masi M, Cellini M, Salvini F, Di Bari C, Dedoni M, Dodi I, de Martino M; Italian Register for HIV infection in children..

Acta Paediatr. 2012 Jul;101(7):e287-95. doi: 10.1111/j.1651-2227.2012.02675.x. Epub 2012 Apr 4.

PMID:
22452359
2.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
3.
4.

Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Santucci MB, Bernardi S, Martino AM, Rossi P, Castelli-Gattinara G.

AIDS. 2007 Nov 30;21(18):2465-72.

PMID:
18025883
5.
7.
8.

Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.

Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul W, Tunthanathip P, Ruxrungtham K; Bamrasnaradura Study Team..

AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125.

PMID:
20156097
9.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group..

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
10.
11.

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.

Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA.

BMC Infect Dis. 2006 Jul 11;6:107.

12.

Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides.

Barreiro P, Soriano V, Casas E, González-Lahoz J.

AIDS. 2002 Jan 25;16(2):245-9.

PMID:
11807309
13.

Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.

Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J; HIV-NAT 013 Study Team..

Int J Infect Dis. 2010 Apr;14(4):e311-6. doi: 10.1016/j.ijid.2009.05.017. Epub 2009 Aug 21.

14.

[Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].

Palacios R, Senise JF, Vaz MJ, Castelo A.

Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):411-5. Spanish.

PMID:
18842235
15.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
16.

Paediatric antiretroviral therapy audit in South London.

Doerholt K, Sharland M, Ball C, DuMont G.

HIV Med. 2002 Jan;3(1):44-8.

17.

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR; Swiss HIV Cohort Study..

Clin Infect Dis. 2008 Oct 15;47(8):1093-101. doi: 10.1086/592113. Erratum in: Clin Infect Dis. 2009 May 15;48(10):1491.

PMID:
18783328
18.

[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].

Brunner J, Seybold U, Gunsenheimer-Bartmeyer B, Hamouda O, Bogner JR; ClinSurv-Studiengemeinschaft (gleichwertiger Beitrag)..

Dtsch Med Wochenschr. 2010 Jun;135(23):1166-70. doi: 10.1055/s-0030-1255124. Epub 2010 May 31. German.

PMID:
20514595
19.

Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.

Mocroft, Horban, Clumeck, Stellbrink, Monforte dA, Zilmer, Kirk, Gatell, Phillips, Lundgren; EuroSIDA Study Group..

HIV Clin Trials. 2006 Nov-Dec;7(6):271-84.

PMID:
17208897
20.

Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.

Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F, Rouzioux C, Blanche S.

J Med Virol. 2007 Sep;79(9):1261-9.

PMID:
17607781

Supplemental Content

Support Center